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Mobilization of hematopoietic stem
cells with the novel CXCR4 antagonist POL6326
(balixafortide) in healthy volunteers—results
of a dose escalation trial
Darja Karpova1,7, Susanne Bräuninger1, Eliza Wiercinska1, Ariane Krämer1, Belinda Stock1, Jochen Graff2,
Hans Martin3, Achim Wach4, Christophe Escot4, Garry Douglas4, Barbara Romagnoli4, Eric Chevalier4,
Klaus Dembowski4, Leon Hooftman4 and Halvard Bonig1,5,6*

Abstract
Background: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing
agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CSF.
Methods: Healthy male volunteer donors with a documented average mobilization response to G-CSF received, following ≥6 weeks wash-out, a 1–2 h infusion of 500–2500 µg/kg of balixafortide. Safety, tolerability, pharmacokinetics
and pharmacodynamics were assessed.
Results: Balixafortide was well tolerated and rated favorably over G-CSF by subjects. At all doses tested balixafortide mobilized HSPC. In the dose range between 1500 and 2500 µg/kg mobilization was similar, reaching 38.2 ± 2.8
CD34 + cells/µL (mean ± SEM). Balixafortide caused mixed leukocytosis in the mid-20 K/µL range. B-lymphocytosis
was more pronounced, whereas neutrophilia and monocytosis were markedly less accentuated with balixafortide
compared to G-CSF. At the 24 h time point, leukocytes had largely normalized.
Conclusions: Balixafortide is safe, well tolerated, and induces efficient mobilization of HSPCs in healthy male volunteers. Based on experience with current apheresis technology, the observed mobilization at doses ≥1500 µg/
kg of balixafortide is predicted to yield in a single apheresis a standard dose of 4× 10E6 CD34+ cells/kg from most
individuals donating for an approximately weight-matched recipient. Exploration of alternative dosing regimens may
provide even higher mobilization responses.
Trial Registration European Medicines Agency (EudraCT-Nr. 2011-003316-23) and clinicaltrials.gov (NCT01841476)
Keywords: PEM-technology, CXCR4, Mobilization, Transplantation, Apheresis, Stem cell, Plerixafor, G-CSF, Clinical trial,
Plasmacytoid dendritic cell
Background
Most autologous and 80% of allogeneic hematopoietic
stem cell transplantations (HSCT) are currently performed with mobilized peripheral blood stem cells [1].
*Correspondence: hbonig@uw.edu
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These can be extracted by apheresis from the circulation
after pretreatment of donors with the cytokine G-CSF,
currently the most commonly used mobilizing agent [1].
Optimal mobilization with G-CSF in donors is relatively
inconvenient as it takes 4–5 days [2–4]. G-CSF treatment, although generally considered safe, is regularly
associated with acute (bone pain, flu-like symptoms,
lethargy [5–8]) and more protracted (BM disruption [9],
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suppression of B-lymphopoiesis [10]) adverse events;
moreover, a considerable list of contra-indications to
G-CSF has been identified over the years, mostly related
to the induction of neutrophila and neutrophil activation, but also to activation of lymphocytes [11]. On the
recipient side, a greater risk of chronic graft-versus-host
disease to G-CSF stimulated PBSCT vs. bone marrowderived grafts has been reported [12]. Consequently, significant activity has been dedicated to the identification
and development of alternative mobilizing agents that
would combine predictable, efficient stem cell mobilization with single dose activity and good tolerability for
both donor and recipient.
The ability of CXCR4 antagonists to rapidly dislodge
stem cells from the marrow has been recognized for
many years [13]. Previously studied compounds were
neither universally well tolerated nor very potent [14].
The only currently approved CXCR4 antagonist plerixafor mobilized a median of 16 CD34+ cells per µL when
administered alone (without G-CSF) in healthy donors
[15], which is barely sufficient to generate a normal-sized
graft in two apheresis sessions.
The synthetic protein epitope mimetic (PEM) peptidic
CXCR4 antagonist POL5551, a close analogue of the
clinical stage compound balixafortide (POL6326), shows
a very wide pharmacodynamic range in preclinical models and at optimal doses even mobilizes more efficiently
than G-CSF [16]. In this clinical phase I dose escalation
trial we evaluated balixafortide with regard to its safety,
tolerability, pharmacokinetics and mobilization efficiency
in healthy male volunteers in comparison to G-CSF.
Balixafortide was well tolerated and rated subjectively
preferable to G-CSF according to the volunteers. Mobilization was rapid; dose-dependency was apparent at doses
up to 1500 µg/kg with an average peak mobilization of
38.2 ± 2.8 CD34 positive cells per µL.

Methods
Volunteers

Volunteers were healthy male HSC donors from the German Stem Cell Donor Registry (DSSD) who had received
a 5-day course of filgrastim (G-CSF, 7.5–10 µg/kg per
day in 2 divided doses) for matched-unrelated stem
cell donation and shown a grossly average mobilization
response (121.6 ± 8.6 CD34+ cells/μL). Additional eligibility (inclusion) criteria for treatment with balixafortide
were the same as for G-CSF mobilized stem cell donation [11]. Between G-CSF mobilization/HSPC donation
and study participation there was a wash-out period of at
least 6 weeks.
Written informed consent was provided prior to performing any study related activities. The study and
all related documents were approved by the local
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Institutional Review Board (IRB) (#324/11) and the
federal medicines agency BfArM (approval #61-39104037635). The trial was registered with the European
Medicines Agency as EudraCT-Nr. 2011-003316-23 and
on clinicaltrials.gov as NCT01841476.
Study drug was administered on an in-patient basis in
the phase I clinical trial unit of Goethe University Medical Center, the ‘Klinisches Studienzentrum Rhein-Main’.
Volunteers were discharged 24 h after treatment, to
return for a follow-up appointment 8–14 days thereafter.
Study design

This was a prospective Phase I open label dose escalation trial; The study design is summarized in Table 1. A
total of 27 volunteers were treated with balixafortide. A
treatment consisted of a single intravenous infusion of
balixafortide in normal saline at doses of 500, 1000, 1500,
2000 and 2500 μg/kg, based on actual weight, followed
by sequential clinical and blood analyses (see below). Initially conceived as a classical 3 + 3 dose escalation design,
the volunteers were assigned to four groups defined by
increasing dose levels of balixafortide (500, 1000, 1500,
and 2000 μg/kg) administered by constant rate infusion
at over 2 h. Subsequently, amendments were added to
test additional modalities: Group 6 received 2500 μg/kg
under the same conditions. Volunteers assigned to Group
5 received a dose level of 2000 μg/kg by an continuously
increasing infusion rate (ramp-infusion instead of constant rate infusion) applied over 2 h. In group 7, a dose
level of 1000 μg/kg was infused over 1 h at a constant
rate and compared (intra-individually) to the 2 h infusion
given with an interval of ≥4 weeks. A second balixafortide treatment was furthermore tested in volunteers from
groups 2, 3 and 6 with groups 2 and 3 receiving 2500 μg/
kg and group 6 given 1500 μg/kg as the second infusion.
In as far as not all volunteers from the initial phase of the
study could be recalled, they were replaced by new volunteers receiving two treatments, to have a group size of at
least 3 for each cross-over modality, explaining the variable dosing group sizes between 3 and 6 (Table 1). Thus, to
allow for intra-individual comparison, 12 donors received
a second dose of balixafortide (2 h constant infusion rate
for all) after a minimum wash-out period of 4 weeks.
Vital signs were monitored immediately prior to and
in the first 24 h after the start of the infusion of balixafortide; serial blood samples were drawn for biochemical
safety profiling and pharmacokinetic/pharmacodynamic
analyses. Given the cationic nature of the compound
[17] the risk of local or systemic symptoms of histamine
release was identified and anti-histamine treatment was
proposed (per protocol) in case of such symptoms. After
completion of the 2000 µg/kg dosing group the protocol
was amended to introduce prophylactic anti-histamine

Karpova et al. J Transl Med (2017) 15:2
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Table 1 Study design
1st treatment
Dose (μg/kg)/infusion
time (h)/infusion rate

2nd treatment
Dose (μg/kg)/
infusion time (h)/
infusion rate

Pharmacokinetics

Group 1
Volunteer 1

500/2/constant

Volunteer 2

500/2/constant

Volunteer 3

500/2/constant

Plasma samples were collected at the indicated times and
kept frozen until immediately before analysis.

_

Pharmacodynamics

Group 2
Volunteer 1

1000/2/constant

2500/2/constant

H

2500/2/constant

H

Volunteer 2

1000/2/constant

Volunteer 3

1000/2/constant

–

Volunteer 4

1000/2/constant

2500/2/constantH

Group 3
Volunteer 1

1000/1/constanth

1000/2/const. rate

Volunteer 2

1000/1/constant

1000/2/const. rate

Volunteer-3

1000/1/constant

1000/2/const. rate

Volunteer 1

1500/2/constant

2500/2/const. rateH

Volunteer 2

h

2500/2/const. rateH

Group 4
1500/2/constant

Volunteer 3

1500/2/constant

–

Volunteer 4

1500/2/constant

2500/2/const. rateH

Volunteer 1

2000/2/constanth

–

Volunteer 2

2000/2/constant

Volunteer 3

2000/2/constanth

Volunteer 4

2000/2/constanth

Volunteer 5

2000/2/constanth

Volunteer 6

2000/2/constanth

Group 5

Group 6
Volunteer 1

2000/2/ramped

Volunteer 2

2000/2/rampedh

Volunteer 3

2000/2/ramped

–

Group 7
Volunteer 1

2500/2/constantH

–

Volunteer 2

2500/2/constantH

1500/2/const. rate

Volunteer 3

2500/2/constantH

1500/2/const. rate

Volunteer 4

2500/2/constantH

1500/2/const. rate

A total of 27 volunteers were treated with 39 doses of balixafortide
In italics volunteers with histamine release associated AE
H

specifically the intra-individual comparison of balixafortide- and G-CSF-induced mobilization of HSPCs. Secondary objectives included pharmacokinetic analyses and
identification of a suitable window for HSPC apheresis.

Anti-histamine premedication

h
Therapeutic anti-histamine treatment upon appearance of likely histamine
release AEs

treatment in the dosage group ≥2500 µg/kg. Volunteers
who received prophylactic or therapeutic anti-histamine
medication are listed accordingly in Table 1.

Blood samples were collected at the indicated times
(Figs. 1, 2, 3, 4, 5 and 6) and kept at room temperature
(maximum 2–3 h.) until immediately before analysis.
Complete blood counts were assessed with the Sysmex
XT1800 hematology analyzer (Norderstedt, Germany).
CD34+ cells were quantified using the single platform
flow cytometry analysis with the SCE Kit [Becton–Dickinson (BD), Heidelberg, Germany] according to the
manufacturer’s instructions and ISHAGE guidelines [18].
In addition, multi-parametric flow cytometric analyses
were performed to quantify co-mobilized mature cell
subsets such as T (CD45+ CD3+), B (CD45+ CD19+)
and NK (CD45+ CD56+ 16+) cells (Multitest, T cells,
BD), T cell subpopulations (CD45+ CD3+ CD4+/
CD8+, Multitest, TBNL cells, BD) and monocytes
(CD45+ CD14+, all from BD). In addition, plasmacytoid dendritic cell progenitors (pro-pDCs) were identified as CD45dimCD34dimCD45RA + CD123high (all
moABs from BD). Lyse-no-wash protocols were used in
conjunction with BD counting beads for direct cell enumeration for CD34+ cells and T cell subsets; all other cell
concentrations were calculated using frequencies relative to directly enumerated cell species, such as CD34+,
CD45+ or CD3+ cells.
Circulating colony-forming units-culture (CFU-C)
were quantified by plating aliquots of lysed peripheral
blood in commercial cytokine-replete methylcellulose
media (StemMACS HSC-CFU lite with Epo, human,
Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany).
Statistical analysis

Unless otherwise mentioned, data are expressed as
mean ± SEM. Descriptive statistics and Student’s t-test
for paired or unpaired analysis (as appropriate) were calculated using Excel. A p < 0.05, Bonferroni-corrected for
multiple testing if appropriate, was considered statistically significant.

Results

Objectives

Safety and tolerability

Primary outcome parameters were safety and tolerability
of balixafortide when compared to G-CSF, pharmacodynamics of mature and immature blood cell mobilization,

A summary of adverse events that were documented
throughout the trial is shown in Table 2. No severe
adverse events (SAEs) were observed. Mild skin reactions

Karpova et al. J Transl Med (2017) 15:2
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b

a

c

d

Fig. 1 Pharmacokinetics. a Cmax (left Y-axis) and AUC (right Y-axis) are plotted as a function of dose (X-axis). Dose-linear pharmacokinetics were
observed. n = 3–6. b Dose-dependent pharmacokinetic profiles are shown. Cmax was reached at the end of infusion and balixafortide was cleared
quickly from the circulation thereafter. n = 3–6. c Comparative pharmacokinetics of balixafortide (1000 µg/kg) infused over 1 vs. 2 h. Cmax was
higher and reached earlier for 1-h dosing, but AUC was similar (data not shown). n = 3. d Comparative pharmacokinetics of linear vs. ramped
infusion rate at the 2000 µg/kg dose level. Cmax was notably higher but AUC was virtually identical for both infusion types. n = 3. Mean ± SEM are
shown throughout

such as flushing, urticaria or local itching were reported
by 1/3, 4/10, 2/7, 8/9 and 7/10 volunteers receiving 500,
1000, 1500, 2000 and 2500 µg/kg of balixafortide respectively. Upon treatment with a combination of H1 and H2
blockers symptoms rapidly abated. These reactions were
rated likely related to study drug.
Three adverse events (AEs) were considered possibly
related to study drug: mild bone pain (1 subject), an unexplained elevation in serum creatinine kinase (2 subjects),
and a systolic blood pressure reading of >150 mmHg (2
subjects).
Constant-slope infusion, tested at the 2000 µg/kg dose
level in three volunteers (group 6), as well as increased
infusion rates (1 vs. 2 h, group 3), tested in paired analyses in three volunteers at the 1000 µg/kg dose level, did
not influence the tolerability of the agent (Table 1).

At the time of follow-up, volunteers were questioned
about their subjective rating of G-CSF vs. balixafortide as
mobilizing agents; there was an overwhelming preference
for balixafortide. See also Table 3 for the questionnaire
and volunteer responses.
Pharmacokinetics

Serial plasma samples were assayed for balixafortide concentrations and pharmacokinetic parameters were calculated using Phoenix WinNonlin 6.4. We observed dose
linearity for both Cmax and AUC (Fig. 1a). The volume of
distribution was approximately 500–600 mL/kg. Balixafortide was cleared from plasma with a terminal half-life
of approximately 5 h over all application schemes and
doses of 5:45 ± 0:35 h (mean ± SD; Fig. 1b). The clearance of balixafortide appeared to be almost equal to the

Karpova et al. J Transl Med (2017) 15:2

glomerular filtration rate suggesting that balixafortide
is mainly cleared through the kidney. Different infusion
durations (1 vs. 2 h) did not notably influence the PK
profile except for an earlier Cmax (Fig. 1c), and the same
applied to ‘constant-slope’ vs. ‘ramp’ infusion (Fig. 1d).
Pharmacodynamics—mobilization of immature cells

At all doses tested, balixafortide infusions quickly resulted
in an increase in circulating HSPCs, as measured phenotypically (CD34+ cells, Fig. 2a) or functionally in colony assays (Fig. 2b). Clonogenicity of balixafortide vs.
G-CSF mobilized CD34+ cells was lower with 1 CFU-C
out of 5.9 ± 0.5 balixafortide mobilized CD34+ cells vs.

a
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1 CFU-C out of 3.2 ± 0.2 CD34+ cells mobilized with
G-CSF (Fig. 2c). At lower doses (500 vs. 1000 vs. 1500 µg/
kg), dose-dependent mobilization was clearly observed,
while the later dose increments to 2000 and 2500 µg/kg
did not result in a commensurate increase in the number
of mobilized HSPC compared to 1500 µg/kg (Fig. 3a, b).
This was confirmed in paired analyses in small cohorts
(Fig. 3c). Therefore, for some analyses all mobilization
data for doses ≥1500 µg/kg are analyzed together. As
such, mean peak mobilization in response to doses of
1500–2500 µg/kg was 38.2 ± 2.8 CD34+ cells/µL (Fig. 3d).
Thus at these doses intra-individual comparison of balixafortide vs. G-CSF induced mobilization revealed that—on

b

c

Fig. 2 Pharmacodynamics: mobilization of immature hematopoietic cells. a, b Dose-dependent mobilization of phenotypically (CD34+ , panel a)
or functionally (CFU-C, panel b) defined stem and progenitor cells (HSPCs). HSPC mobilization was observed at all dose levels. Mobilization at the
lowest dose level peaked 1 h after the end of the infusion and was delayed after higher doses. Dose dependence was observed for the first three
dosing steps (n = 3–6, mean ± SEM). c The ratio between circulating CD34+ cells and CFU-C is shown for all doses. Clonogenicity of balixafortide
mobilized CD34+ tended to be lower than for G-CSF mobilized CD34+ cells. Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3–6

Karpova et al. J Transl Med (2017) 15:2
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a

b

c

d

Fig. 3 Mobilization of immature hematopoietic cells: comparison with G-CSF. Baseline circulating CD34+ cells, balixafortide mobilized CD34+ cells
(incremental balixafortide dose as indicated on X-axis) and G-CSF mobilized CD34+ cells (same G-CSF dose for all groups, see “Methods” section)
are displayed in (a). Corresponding fold-increase data are shown in (b). Symbols represent individual values, the short horizontal bar and whiskers
mean ± SEM. n = 3–6. c Intra-individual comparison of peak mobilization with 1000 vs. 2500 µg/kg (left panel, n = 3) or 1500 vs. 2500 µg/kg (right
panel, n = 6) of balixafortide is shown. 2500 µg/kg balixafortide mobilized more CD34+ cells than 1000 µg/kg, whereas no difference between
peak mobilization with 1500 vs. 2500 µg/kg was observed. Symbols represent individual values. d The good correlation between effectiveness of
G-CSF vs. balixafortide with respect to CD34+ cell mobilization is displayed for balixafortide doses between 1500 and 2500 µg/kg n = 14. Symbols
represent individual values (constant rate only)

average—the G-CSF regimen was about three times as
effective as the CXCR4 antagonist. There appeared to be
a good correlation between the two mobilizing agents
(Fig. 3d), suggesting that—as had been shown in mice [16,
19]—good mobilizers mobilize efficiently with either agent
and poor mobilizers are refractory to both.
Peak mobilization at the 500 µg/kg dose was observed
1 h after the end of the balixafortide infusion/after reaching Cmax (Figs. 1b, 2a). At higher doses, the observed
mobilization peak appeared later, approximately 4 h
after the end of the infusion. Thereafter, the number of
circulating CD34+ cells slowly decreased but remained

elevated beyond baseline at the 24 h time point for all
except the lowest dose (Fig. 2a, b). Constant-slope (ramp)
vs. constant-rate infusions (at 2000 µg/kg only) had no
discernible effect on stem cell mobilization efficiency,
and the same applied to infusion rate (1 vs. 2 h) (Fig. 4).
A population of “stem cells” co-expressing CD45RA
and CD123, previously described in blood of plerixaformobilized donors and identified as plasmacytoid dendritic cell progenitors (pro-pDCs) [20], was detected at
high frequencies (22.4 ± 2.3% of SSCdim/FSCmid-hi/
CD45dim/CD34+ cells) after balixafortide-treatment,
but was rare after G-CSF (Fig. 5).

Karpova et al. J Transl Med (2017) 15:2
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a

b

c

d

Fig. 4 Mobilization of immature hematopoietic cells: effects of infusion velocity and rate. a, b Inter-individual comparison of CD34+ cell mobilization after infusion of balixafortide over 1 vs. 2 h demonstrates equivalent mobilization kinetics (a) and peak mobilization responses (b). This cohort
received only a single course of G-CSF, hence the data shown for G-CSF mobilization with each of the baselines and balixafortide treatments are
the same. Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3. c, d Comparison of CD34+ cell mobilization after ramped vs. constant rate infusion of balixafortide demonstrates equivalent mobilization kinetics (c) and peak mobilization responses (d).
Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3

Pharmacodynamics—mobilization of mature
hematopoietic cells

Stem cell mobilization was accompanied with mixed
leukocytosis affecting all cell lineages. It followed the
same kinetics as stem cell mobilization and was dosedependent as well as short-lived. At balixafortide doses
of 1500–2500 µg/kg white blood counts (WBCs) of
25.3 ± 1.4 × 10*3 WBC/µL were reached, i.e. balixafortide mobilized approximately half as many mature cells
as G-CSF (Fig. 6a). The lineage distribution of mature
leukocytes differed markedly between both agents, in
that balixafortide mobilized higher relative and absolute
numbers of B-cells and fewer myeloid cells (Fig. 6b, c).
The ratio between T-lymphocytes and CD34+ cells was
26.2 ± 1.98:1 in G-CSF mobilized blood, vs. 95.7 ± 8.9:1

in balixafortide mobilized blood, predicting that apheresis products from balixafortide mobilized donors will
contain more T-cells than from G-CSF treated donors.
Within the T cell population the proportion of T helper
(CD4+) and cytotoxic T cells (CD8+) was very similar
between the differently mobilized blood specimens as
well as compared to steady state (baseline) (Fig. 6d).

Discussion
We performed a Phase I clinical trial to directly compare
the novel CXCR4 antagonist balixafortide with the standard mobilizing agent G-CSF, with regard to the following parameters: safety and tolerability, pharmacokinetic
profile, and pharmacodynamic effects; the latter were
defined as mobilization volumes of immature and mature

Karpova et al. J Transl Med (2017) 15:2
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Fig. 5 Mobilization of plasmacytoid dendritic cell (pDC) progenitors. Displayed are representative flow cytograms of putative pro-pDCs (defined as
CD34dimCD45dimCD45RA+CD123high) detected in G-CSF (top) or balixafortide (bottom) mobilized blood. Mean (±SEM) percentages of pDC progenitors within the HSPC fraction CD34+CD45dim detected in all G-CSF and balixafortide (1st treatment, constant infusion rate, 2 h, Table 1) mobilized
specimen (n = 21) are shown in the bottom

blood cells. At the doses tested, balixafortide was associated with few adverse effects, and none of these were
dose limiting. Skin symptoms compatible with possible
local histamine release syndrome were observed with
some regularity but could easily be managed with routine
co-administration of anti-histamines.
Mechanistically, mobilization with CXCR4 antagonists
like balixafortide involves a rather short-lived interference with stem cell retention in the bone marrow [13].
Therefore some of the proposed (albeit never robustly
substantiated) long-term adverse effects of G-CSF should
not rationally be associated with balixafortide treatment.
Specifically, we speculate that, unlike G-CSF, balixafortide may be a safe mobilizing agent for patients (and
donors) with autoimmune conditions [21, 22] as well as
sickle cell disease [23, 24]. Formal questionnaires also
confirm good tolerability and, in fact, indicate a preference for balixafortide vs. GCSF, although the study setting may have favored balixafortide.
The higher balixafortide doses tested in this study
mobilized 38.2 ± 2.8 CD34+ cells/µL. In view of the

currently available technologies [25, 26] this is sufficient to generate a stem cell product with an average of
5× 10E6 CD34 + donor cells/kg as per a single apheresis;
this constitutes an adequate number of cells for the average PBSCT [i.e. >4× 10E6/kg (weight of recipient), and
would even accommodate patients with a body weight
that is somewhat higher than their donor. That said, data
in mice [16] and cynomolgus monkeys (unpublished)
indicated a semi-logarithmic dose-response relationship
with a high ceiling; extrapolating from these data we postulate that further dose increments of balixafortide are
possible. Further studies with higher doses of balixafortide are therefore warranted as meaningfully higher stem
cell yields may be achieved—provided these doses are
well tolerated.
The comparator agent in our study was G-CSF given
in split doses as is routine practice in our center [7];
the rationale is twofold: more efficient mobilization and
potentially better tolerability [27–30]. The alternative
regimen that is widely used in the USA employs the same
daily dose but makes use of a single injection for which

Karpova et al. J Transl Med (2017) 15:2
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Fig. 6 Pharmacodynamics: mobilization of mature hematopoietic cells. a Balixafortide induces dose-dependent leukocytosis with the same kinetics as observed for CD34+ cells (n = 3–6, mean ± SEM); -fold difference between mature cell mobilization with balixafortide and G-CSF was equivalent to that for CD34+ cells. Differential mobilization of leukocyte subsets was observed, with lower monocyte (b), higher B-cell (c), but similar T-cell
(total, CD4+ and CD8+ T-cells, d mobilization after balixafortide vs. G-CSF induced mobilization (n = 3–6, mean ± SEM). G-CSF was administered at
the same dose in all groups; the symbol used links mobilization results to a certain balixafortide dosing group

average CD34+ cell counts in the mid-sixties’ range (per
µL) were reported [6] i.e. less than two-thirds of what is
achieved with split-dose G-CSF. Thus the advantage in
efficiency of single-dose G-CSF vs. balixafortide at the
doses tested here would be less than twofold.
High frequencies of a population presumed to represent precursors of plasmacytoid dendritic cells (propDCs) were previously detected in plerixafor-mobilized
blood [20] and were also found by us in balixafortidemobilized blood (Fig. 5). This indicates a substance
class specific mobilization effect and is in fact in line
with reports showing the importance of the CXCR4/
CXCL12 pathway in pro-pDC development (and retention) in mice [31]. The biological function of pro-pDCs
in a graft is unclear. As they have been associated with

immunomodulatory functions [32] such as promotion of
regulatory T cell differentiation [33, 34], it is tempting to
speculate about a possible role in modulating graft-versus-host disease (GvHD). Indeed, in a cohort of patients
receiving a plerixafor-mobilized graft only 1/20 developed acute GvHD 3° or 4° [15] which is markedly less
than would be expected with G-CSF-mobilized blood
[12, 35, 36] and which was not accompanied by an excessive relapse rate. These data are potentially meaningful
given the much higher T-cell dose co-transplanted with a
CXCR4 antagonist-mobilized graft.
As all other mobilizing regimes, mobilization by
balixafortide was associated with marked leukocytosis;
the-fold difference for mature and immature cell mobilization between G-CSF and balixafortide was quite

Karpova et al. J Transl Med (2017) 15:2
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Table 2 Safety and tolerability of balixafortide. Summary of adverse events
Dose (μg/kg)

500

1000

1000

1500

2000

2000

2500

Infusion time/rate

2 h./const.

2 h./const.

1 h./const.

2 h./const.

2 h./const.

2 h./ramp

2 h./const.

n Volunteers

3

7

3

7

6

3

10

Volunteers with AE

1

5

1

2

6

2

7

1

4

1

4

Erythema
Pruritus
Infusion site erythema

2

1

1

Infusion site pruritus

2
1

1

Urticaria

1

Flushing

1
1

Hypoasthesia oral
BP increase

7
2

1
2

2

Blood CK increased

2

Infusion site irritation

1

Feeling hot

1

Muscle tightness

1

Headache

1

Hypoasthesia

1

Throat tightness

1
1

Bone pain

1

Vertigo

1

A total of 27 volunteers were treated with 39 doses of balixafortide. Therefore some volunteers (12) were included in two different groups, when adverse events per
dose-group were assessed. Responses to all items were binary (yes/no), not quantitative; multiple responses were possible

Table 3 Safety and tolerability of balixafortide. Subjective
rating
Side effects in the course of treatment with:
Abdominal pain

G-CSF Balixafortide
2

0

Bone pain

24

0

Headache

11

1

1

13

Skin reactions
Flu-like symptoms
Vomiting

21

0

0

1

Palpitation

1

0

Fever

2

0

0

1

Sweating
Fatigue
Insomnia

11

4

0

1

The treatment is
Easy to use

7

29

Acceptable

13

30

2

32

More convenient overall

similar. However, the distribution of leukocyte subtypes
was markedly different; specifically the virtually diagnostic left-shifted neutrophilia in G-CSF treated volunteers [2, 5] was not observed after balixafortide. These
observations support the prediction that balixafortide

mobilizes without stimulation and lineage skewing and
might thus be suitable for patients in whom such could
result in undesirable side effects.
One of the desired features of a mobilizing agent is predictability of efficacy. Mouse data clearly indicate that
mobilization efficiency is dominated by genetics [37, 38]
but that the delta or-fold difference (e.g. between C57Bl/6
and DBA/2 mice) is much closer for CXCR4 antagonists
than for G-CSF [16]. Although differences in G-CSF
mobilization efficiency in our trial were less apparent
due to inclusion criteria (average mobilization), our data
clearly confirm the strong donor-inherent component
for the efficiency of stem cell mobilization per se on the
one hand and less pronounced variability in mobilization
response with balixafortide on the other hand.

Conclusion
We have demonstrated that HSPC mobilization with
balixafortide can be both efficient and predictable; more
potent mobilization may be achievable with higher doses
of this agent, as future studies may be able to show. Balixafortide treatment was safe and well tolerated. Because
of its mechanism of action along with its rapid elimination, this stem cell mobilizing agent can be considered
an option for many of the patients and donors with
contra-indications to G-CSF. Its brisk mobilization after

Karpova et al. J Transl Med (2017) 15:2

one single dose is also highly convenient for donors and
apheresis centers. In aggregate, balixafortide could be
developed as an alternative single-agent mobilizing agent
for patients and donors alike. By extension, our work
also demonstrates the potential of PEM technology for
rational drug design.
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